GLP1R and colorectal neoplasm: Wang et al, by retrospective database search without randomized procedure to minimize the potential difference across experimental and control groups, noticed that the overall GLP-1 receptor agonists were associated with a lower risk of colorectal tumors, especially in obese participants[12,13].